We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > hepatitis C drugs

News List

Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir worldpharmanews
April 28, 2021
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19.
Five hepatitis C drugs to become available on the NHS pharmaceutical-technology
May 05, 2019
A deal signed by pharmaceutical companies AbbVie, Gilead Sciences and Merck Sharp and Dohme (MSD) will see five new hepatitis C drugs become available on the UK National Health Service (NHS).
Merck loses bid to revive $200 million Gilead verdict at US high court expressbpd
January 09, 2019
Merck had urged the Supreme Court to place limits on the doctrine of ‘unclean hands’ that can prevent plaintiffs from winning lawsuits if they acted in bad faith.
Gilead to launch generic versions of hepatitis C drugs pharmaceutical-technology
September 27, 2018
Gilead Sciences has revealed plans to introduce generic versions of its Epclusa and Harvoni in the US for the treatment of chronic hepatitis C virus infection.